This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dong, C. Articles by Goldschmidt-Clermont, P. J. Search for Related Content PubMed PubMed Citation Articles by Dong, C. Articles by Goldschmidt-Clermont, P. J. Related Collections Risk Factors Genetics of cardiovascular disease

(Circulation Research. 2001;88:855.)
© 2001 American Heart Association, Inc.

Editorial

ABCA1 Single Nucleotide Polymorphisms

Snipping at the Pathogenesis of Atherosclerosis

Chunming Dong, Joseph R. Nevins, Pascal J. Goldschmidt-Clermont

From the Division of Cardiology, Department of Medicine (C.D., P.J.G.-C.) and the Department of Genetics (J.R.N., P.J.G.-C.), Duke University Medical Center, Durham, NC.

Correspondence to Pascal J. Goldschmidt-Clermont, Division of Cardiology, Duke University Medical Center, 7504 Duke Hospital North, Box 3845, Durham NC 27710. E-mail golds017@mc.duke.edu

Key Words: polymorphisms • Tangier disease • HDL cholesterol • atherosclerosis • genetics

	Introduction

 
Identification of genetic variants that predispose to complex traits is a major goal of the biomedical investigators of the post–Human Genome Project era, for whom the entire reference genome sequence and some of its frequent variants are a given. The most common form of genomic variation is the single nucleotide polymorphism (SNP). Indeed, SNP search has become a busy industry, as evidenced by the panoply of industrial methodologies. Although common diseases do not follow Mendelian inheritance patterns and the contribution of heredity to their pathogenesis may be hard to pinpoint, the genetic determinants of these complex traits are tractable. Knowledge of genetic predisposition will have broad consequences for preclinical diagnostics, preventive maneuvers, and therapeutic strategies.

Coronary heart disease (CHD) constitutes the major public health burden of industrialized nations. It causes nearly half a million deaths in the United States yearly (making it the single leading cause of death in the United States) and accounts for 13.7% of total mortality worldwide (7,375,000 deaths, according to World Health Organization estimates for 1998).¹ CHD is multifactorial, and its progression is known to be influenced by risk factors such as cigarette smoking, elevated blood pressure, diabetes mellitus, obesity, aging, elevated serum LDL-cholesterol (LDL-C), and low-serum HDL cholesterol (HDL-C). Thus, plasma lipoprotein disturbances are among the most common biochemical abnormalities observed in patients with CHD. Moreover, many patients with CHD do not have markedly elevated LDL-C but rather have low HDL-C levels, either alone or accompanied by hypertriglyceridemia.

An important goal is to determine why . . . [Full Text of this Article]